QC
MRVI icon

Quantessence Capital’s Maravai LifeSciences MRVI Stock Holding History

Quantessence Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,727
Closed -$30.8K – 109
2025
Q3 		$30.8K Buy
+10,727
New +$27.4K 0.01% 173

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quantessence Capital's MRVI Position: Q4 2025 in Review

Quantessence Capital sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 10,727 shares — an estimated $30.8K sold.

Quantessence Capital first reported a position in MRVI in Q3 2025 and held it in 1 quarter. The position peaked at $30.8K in Q3 2025. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

  • Quantessence Capital reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
  • Quantessence Capital sold 10,727 Maravai LifeSciences shares in Q4 2025, an estimated $30.8K.
  • Quantessence Capital first reported a position in Maravai LifeSciences in Q3 2025 and held it in 1 quarter.
  • Quantessence Capital's Maravai LifeSciences position peaked at $30.8K in Q3 2025.
  • 159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Quantessence Capital's 13F filing for Q4 2025, filed 17 Feb 2026.